Discovery of 3,4-diaminocyclobut-3-ene-1,2-dione-based CXCR2 receptor antagonists for the treatment of inflammatory disorders

Current Topics in Medicinal Chemistry

Volumn 10, Issue 13, 2010, Pages 1339-1350

  Dwyer, Michael P ^a   Biju, Purakattle ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

2 dione; 3,4 diaminocyclobut 3 ene 1; CXCR2; SCH 527123

Indexed keywords

3,4 DIAMINOCYCLOBUT 3 ENE 1,2 DIONE DERIVATIVE; AZ 8309; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR2; REPARIXIN; SB 332235; SB 656933; SCH 527123; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DELAYED GRAFT FUNCTION; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; INFLAMMATORY DISEASE; NONHUMAN; PSORIASIS; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOBUTANES; DRUG DISCOVERY; HUMANS; INFLAMMATION; MOLECULAR CONFORMATION; RECEPTORS, CCR2; STEREOISOMERISM;

EID: 77955609137     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610791561246     Document Type: Article

References (74)

1. Bunting, M.; Harris, E.S.; Mclntyre, T.M.; Prescott, S.M.; Zimmerman, G.A. Leukocyte adhesion and deficiency syndromes: Adhesion and tethering defects involving beta 2 integrins and selectin ligands. Curr. Opin. Hematol., 2002, 9(1), 30-35.
2. Adams, D.H.; Lioyd, A.R. Chemokines: Leucocyte recruitment and activation cytokines. Lancet, 1997, 349(9055), 490-496.
3. Saunders, J.; Tarby, C.M. Opportunities for novel therapeutic agents acting on chemokine receptors. Drug Discov. Today, 1999, 4(2), 80-92.
4. Gura, T. Immunology: Chemokines take center stage in inflammatory ills. Science, 1996, 272(5264), 954-960.
5. Skelton, N.J.; Quan, C.; Reilly, D.; Lowman, H. Structure of a CXC chemokine-receptor fragment in complex with interleukin-8. Structure, 1999, 7(2), 157-168.
6. Horuk, R. Chemokine receptors. Cytokine Growth Factor Rev., 2001, 72(4), 313-335.
7. Moser, B.; Dewald, B.; Barella, L.; Schumacher, C.; Baggiolini, M.; Clark-Lewis, I. Interleukin-8 antagonists generated by N-terminal modification. J. Biol. Chem., 1993, 268(10), 7125-7128.
8. Holmes, W.E.; Lee, J.; Kuang, W.J.; Rice, G.C.; Wood, W.I. Structure and functional expression of a human interleukin-8 receptor. Science, 1991, 253(5025), 1278-1280.
9. Murphy, P.M.; Tiffany, H.L. Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science, 1991, 253(5025), 1280-1282.
10. Walz, A.; Burgener, R.; Carr, B.; Baggiolini, M.; Kunkel, S.L.; Strieter, R.M. Structure and neutrophil activating properties of a novel inflammatory peptide (ENA-78) with homology to interleu-kin-8. J. Exp. Med., 1991, 774(6), 1355-1362.
11. Wolf, M.; Del-gado, M.B.; Jones, S.A.; Dewald, B.; Clark-Lewis, B.; Baggiolini, M. Granulocyte chemotactic protein 2 act via both IL-8 receptors, CXCR1 and CXCR2. Eur. J. Immunol., 1998, 28(1), 164-170.
12. Mukaida, N. Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am. J. Physiol., 2003, 284(4,Pt.1), L566-L577.
13. Baggiolini, M.; Dewald, B.; Moser, B. Interleukin-8 and related chemotactic cytokines CXC and CC chemokines. Adv. Immunol., 1994, 55, 97-179.
14. Luster, A.D. Chemokines - Chemotactic cytokines that mediate inflammation. N. Engl. J. Med., 1998, 338(7), 436-445.
15. White, J.R.; Lee, J.M.; Young, P.R.; Hertzberg, R.P.; Jurewicz, A.J.; Chaikin, M.A.; Widdowson, K.L.; Foley, J.J.; Martin, L.D.; Griswold, D.E.; Sarau, H.M. Identification of a potent, selective non-peptide antagonist that inhibits interleukin-8-induced neutrophil migration. J. Biol. Chem., 1998, 275(17), 10095-10098.
16. Keatings, V.M.; Collins, R.D.; Scott, D.M.; Barnes, P. Differences in interleukin-8 and tumor necrosis factor-a in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. J. Respir. Crit. Care Med., 1996, 153(2), 530-534.
17. Hay, D.W.; Sarau, H.M. Interleukin-8 receptor antagonists in pulmonary diseases. Curr. Opin. Pharmacol., 2001, 1(3), 242-247.
18. Donnelly, L.E.; Barnes, P.J. Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends in Pharmacol. Sci., 2006, 27(10), 546-553.
19. Cacalano, G.; Lee, J.; Kikly, K.; Ryan, A.M.; Pitts-Meek, S.; Hult-gren, B.; Wood, I.; Moore, W. Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog. Science, 1994, 265(5172), 682-684.
20. Widdowson, K., Veber, D.F., Jurewicz, A.J., Nie, H., Hertzberg, R.P., Holl, W., Sarau, H.M. In: Discovery and characterization of potent, small molecule interleukin-8B receptor antagonists. Pep-tides 1996, Ramage, R., Epton, R., Eds., Mayflower Scientific: Kingswinford, 1998, pp. 87-70.
21. Widdowson, K.; Nie, H.; Jurewicz, A.J.; Hertzberg, R.P.; Sarau, H.M.; Foley, J.J.; Lee, J., White, J.R., Veber, D.F. The role of the anionic groups in the receptor binding or interleukin-8 antagonists. Lett. Pept. Sci., 1998, 5(2-3), 235-239.
22. Li, J.J. Small molecule interleukin-8 modulators. Expert Opin. Ther. Patents, 2001, 11(12), 1905-1910.
23. Gao, A.; Metz, W.A. Unraveling the chemistry of chemokine receptor ligands. Chem. Rev., 2003, 103(9), 3733-3752.
24. Busch-Peterson, J. Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases. Curr. Top. Med. Chem., 2006, 6(13), 1354-1362.
25. Bizzarri, C.; Beccari, A.R.; Bertini, R.; Cavicchia, M.R.; Giorgini, S.; Allegretti, M. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as therapeutic targets. Pharmacol. Ther., 2006, 112, 139-149.
26. Busch-Petersen, J.; Wang, Y. Phenol-containing antagonists of the CXCR2 receptor. Expert Opin. Ther. Patents, 2008, 18(6), 629-637.
27. Govindaraju, V.; Michoud, M.-C.; Al-Chalabi, M.; Ferraro, P.; Powell, W. S.; Martin, J.G. Interleukin-8: novel roles in human airway smooth muscle cell contraction and migration. Am. J. Phys., 2006, 291(5,Pt.1), C957-C965.
28. Reutershan, J. CXCR2 -the receptor to hit? Drug News Perspect., 2006, 19(10), 615-623.
29. Panina, P.; Mariani, M.; D'Ambrosio, D. Chemokine receptors in chronic obstructive pulmonary disease (COPD). Curr. Drug Targets, 2006, 7(6), 669-674.
30. Barnes, P.J. New molecular targets for the treatment of neutrophilic diseases. J. Allergy Clin. Immunol., 2007, 119(5), 1055-1062.
31. White, J.R.; Sarau, H.M. IL-8 receptor antagonist: basic research and clinical utility. In: Chemokine Biology-Basic Research and Clinical Application; Moser, B., Letts, G.L., Neote, K., Eds.; Birkhaeuser Verlag: Basel, Switzerland, 2007, vol. 2, pp. 89-102.
32. Chapman, R.W.; Phillips, J.E.; Hipkin, R.W.; Curran, A. K.; Lundell, D.; Fine, J.S. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol. Therap., 2009, 121, 55-68.
33. Butera, J.A.; Antane, M.M.; Antane, S.A.; Argentieri, T.M.; Freeden, C.; Graceffa, R.F.; Hirth, B.H.; Jenkins, D.; Lennox, J.R.; Matelan, E.; Norton, N.W.; Quagliato, D.; Sheldon, J.H.; Spinelli, W.; Warga, D.; Wojdan, A.; Woods, M. Design and SAR of novel potassium channel openers targeted for urge urinary incontinence. 1. N-cyanoguanidine bioisosteres possessing in vivo bladder selectivity. J. Med. Chem., 2000, 43(6), 1187-1202.
34. Kinney, W.A.; Abou-Gharbia, M.; Garrison, D.T.; Schmid, J.; Kowal, D.M.; Bramlett, D.R.; Miller, T.L.; Tasse, R.P.; Zaleska, M.M.; Moyer, J.A. Design and synthesis of [2-(8,9-Dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)-ethyl]phosphonic acid (EAA-090), a potent N-methyl-D-aspartate antagonist, via the use of 3-cyclobutene-1,2-dione as an achiral a-amino acid bioisostere. J. Med. Chem., 1998, 41(2), 236-246.
35. Merritt, J.R.; Rokosz, L.L.; Nelson, K.H.; Kaiser, B.; Wang, W.; Stauffer, T. M.; Ozgur, L.E.; Li, G.; Baldwin, J.J.; Dwyer, M.P.; Chao, J.; Taveras, A. Synthesis and structure-activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists. Bioorg. Med. Chem. Lett., 2006, 16, 4107-4110.
36. st ACS National Meeting, Atlanta, GA, United States, March 20-26, 2006.
37. Dwyer, M.P.; Yu, Y.; Chao, J.; Aki, C.; Chao, J.; Biju, P.; Giri-javallabhan, V.; Rindgen, D.; Bond, R.; Mayer-Ezel, R.; Jakway, J.; Hipkin, R.W.; Fossetta, J.; Gonsiorek, W.; Bian, H.; Fan, X.; Ter-minelli, C.; Fine, J.; Lundell, D.; Merritt, J.R.; Rokosz, L.L.; Kaiser, B.; Li, G.; Wang, W.; Stauffer, T.M.; Ozgur. L.E.; Taveras, A.G. Discovery of 2-Hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5-methylfuran-2-yl)propyl]amino]-3,4-dioxo-cyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable cxcr2/cxcr1 receptor antagonist. J. Med. Chem., 2006, 49(26), 7603-7603.
38. Chao, J.; Taveras, A.G.; Chao, J.; Aki, C.; Dwyer, M.; Yu, Y.; Purakkattle, B.; Rindgen, D.; Jakway, J.; Hipkin, W.; Fosetta, J.; Fan, X.; Lundell, D.; Fine, J.; Minnicozzi, M.; Phillips, J.; Merritt, J.R. C(4)-Alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists. Bioorg. Med. Chem. Lett., 2007, 17, 3778-3783.
39. Yu, Y.; Dwyer, M.P.; Chao, J.; Aki, C.; Chao, J.; Purakkattle, B.; Rindgen, D.; Bond, R.; Mayer-Ezel, R.; Jakway, J.; Qiu, H.; Hip-kin, R.W.; Fossetta, J.; Gonsiorek, W.; Bian, H.; Fan, X.; Terminelli, C.; Fine, J.; Lundell, D.; Merritt, J.R.; He, Z.; Lai, G.; Wu, M.; Taveras, A.G. Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists. Bioorg. Med. Chem. Lett., 2008, 18, 1318-1322.
40. Lai, G.; Merritt, J.R.; He, Z.; Feng, D.; Chao, J.; Czarniecki, M.F.; Rokosz, L.L.; Stauffer, T.M.; Rindgen, D.; Taveras, A.G. Synthesis and structure-activity relationships or new disubstituted phenyl-containing 3,4-diamino-3-cyclobutene-1,2-diones as CXCR2 receptor antagonists. Bioorg. Med. Chem. Lett., 2008, 18, 1864-1868.
41. Biju, P.; Taveras, A.G.; Dwyer, M.P.; Yu, Y.; Chao, J.; Hipkin, R.W.; Fan, X.; Rindgen, D.; Fine, J.; Lundell, D. Fluoroalkyl a side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists. Bioorg. Med. Chem. Lett., 2009, 19, 1431-1433.
42. Aki, C.; Chao, J.; Ferreira, J.A.; Dwyer, M.P.; Yu, Y.; Chao, J.; Merritt, J.R.; He, Z.; Lai, G.; Wu, M.; Hipkin, R.W.; Fan, X.; Gonsiorek, W.; Fossetta, J.; Rindgen, D.; Fine, J.; Lundell, D.; Taveras, G.; Biju, P. Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region. Bioorg. Med. Chem. Lett., 2009, 19, 4446-4449.
43. Chao, J.; Taveras, A.G.; Aki, C.J. Synthesis of functionalized hy-droxyl-thiophene motifs as amido- and sulfonamide-phenol bioisosteres. Tetrahedron Lett., 2009, 50, 5005-5008.
44. Biju, P.; Taveras, A.; Yu, Y.; Zheng, J.; Chao, J.; Rindgen, D.; Jakway, J.; Hipkin, R.W.; Fossetta, J.; Fan, X.; Fine, J.; Qiu, H.; Merritt, J.R.; Baldwin, J.J. 3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists. Bioorg. Med. Chem. Lett., 2008, 18, 228-231.
45. th ACS National Meeting, Boston, MA, United States, August 19-23, 2007.
46. Biju, P., Taveras, A.G., Yu, Y., Zheng, J., Hipkin, R.W., Fossetta, J., Fan, X., Fine, J., Lundell, D. 3,4-Diamino-1,2,5-thiadiazole as a potent and selective CXCR2 antagonists. Bioorg. Med. Chem. Lett., 2009, 19, 1434-1437.
47. th ACS National Meeting, New Orleans, LA, United States, March 23-27, 2003.
48. McCleland, W.; Davis, R.S.; Palovich, M.R.; Widdowson, K.L.; Werner, M.L.; Burman, M.; Foley, J.J.; Schmidt, D.B.; Sarau, H.M.; Rogers, M.; Salyers, K.L.; Gorycki, P.D.; Roethke, T.J.; Stelman, G.J.; Azzarano, L.M.; Ward, K.W.; Busch-Peterson, J. Comparison of N,N'-diarylsquaramides and N,N'-diarylureas as antagonists of the CXCR2 chemokine receptor. Bioorg. Med. Chem. Lett., 2007, 17, 1713-1717.
49. Liu, S.; Liu, Y.; Wang, H.; Ding, Y.; Wu, H.; Dong, J.; Wong, A.; Chen, S.-H.; Li, G.; Chan, M.; Sawyer, N.; Gervais, F.G.; Henault, M.; Kargman, S.; Bedard, L.L.; Han, Y.; Friesen, R.; Lobell, R.B.; Stout, D.M. Design, synthesis, and evaluation of novel 3-amino-4-hydrazine-cyclobut-3-ene-1,2-diones as potent and selective CXCR2 chemokine receptor antagonists. Bioorg. Med. Chem. Lett., 2009, 19, 5741-5745.
50. Press, N.J.; Watson, S.J.; Porter, D. Preparation of arylamino het-erocyclylmethyl cyclobutenediones as antiinflammatories. WO 148790A1, 2008.
51. Gonsiorek, W.; Fan, X.; Hesk, D.; Fossetta, J.; Qiu, H.; Jakway, J.; Billah, M.; Dwyer, M.; Chao, J.; Deno, G.; Taveras, A.; Lundell, D.J.; Hipkin, R.W. Pharmacological Characterization of Sch 527123, a Potent Allosteric CXCR1/CXCR2 Antagonist. J. Pharm. Exp. Ther., 2007, 322(2), 477-485.
52. Chapman, R.W.; Minnicozzi, M.; Celly, C.S.; Phillips, J.E.; Kung, T.T.; Hipkin, R.W.; Fan, X.; Rindgen, D.; Deno, G.; Bond, R.; Gonsiorek, W.; Billah, M.M.; Fine, J.S.; Hey, J.A. A novel, orally active CXCR1/CXCR2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperpla-sia in animal models of pulmonary inflammation. J. Pharm. Exp. Ther., 2007, 322(2), 486-493.
53. Thatcher, T.H.; McHugh, N.A.; Egan, R.W.; Chapman, R.W.; Hey, J.A.; Turner, C.K.; Redonnet, M.R.; Seweryniak, K.E.; Sime, P.J.; Phipps, R.P. Role of CXCR2 in cigarette smoke-induced inflammation. Am. J. Physiol. Lung Cell Mol. Physiol., 2005, 289, L322-L328.
54. Taveras, A.G.; Billah, M.; Lundell, D.; Kreutner, W.; Jakway, J.; Bober, L.A.; Chao, J.; Biju, P.; Yu, Y. Combination treatments for chemokine-mediated diseases. WO 080053A1, 2003.
55. Waugh, D.J.J.; Wilson, C. The Interleukin-8 pathway in cancer. Clin. Cancer Res., 2008, 14(21), 6735-6741.
56. Singh, S.; Sadanandam, A.; Nannura, K.C.; Varney, M.L.; Mayer-Ezell, R.; Bond, R.; Singh, R.K. Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. Clin. Cancer Res., 2009, 15(7), 2380-2386.
57. Kanniess, F.; Khalilieh, S.; Ludwig-Sengiel, A.; Stryszak, P.; Soni, P.; Holz, O. SCH 527123, a CXCR2 antagonist, inhibits ozone-induced airway neutrophilia. Eur. Resp. J., 2007, 30(Suppl. 1), 209s.
58. Holz, O.; Tal-Singer, R.; Kanniess, F.; Simpson, K.J.; Gibson, A.; Vessey, R.S.J.; Janicki, S.; Magnussen, H.; Jorres, R.A.; Richter, K. Validation of the human ozone challenge model as a tool for assessing anti-inflammatory drugs in early development. J. Clin. Pharm., 2005, 45, 498-503.
59. Study to Evaluate the Safety and Dose-Range of SCH 527123 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD). (NCT00441701, Study P04592AM1). http://www.clinicaltrials.gov/, [Accessed September 2009].
60. Neutrophilic Asthma Study with SCH 527123 (NCT00632502, Study P05365AM2). http://www.clinicaltrials.gov/, [Accessed September 2009].
61. Efficacy and Safety of SCH 527123 in Subjects with Allergen-Induced Asthma (NCT00688467, Study P05363). http://www.clinicaltrials.gov/, [Accessed September 2009].
62. A study to assess the clinical effects of SCH 527123 in psoriasis (NCT00684593, study P04481). http://www.clinicaltrials.gov/ [accessed: September 2009].
63. Ho, K.-K.; Auld, D.S.; Bohnstedt, A.C.; Conti, P.; Dokter, W.; Erickson, S.; Feng, D.; Inglese, J.; Kingsbury, C.; Kultgen, S.G.; Liu, R.-Q.; Masterson, C.M.; Ohlmeyer, M.; Rong, Y.; Roose-boom, M.; Roughton, A.; Samama, P.; Smit, M.-J.; Son, E.; Van der Louw, J.; Vogel, G.; Webb, M.; Wijkmans, J.; You, M. Imida-zolylpyrimidine based CXCR2 chemokine receptor antagonists. Bioorg. Med. Chem. Lett., 2006, 16, 2724-2728.
64. Bruno, O.; Brullo, C.; Bondavalli, F.; Schenone, S.; Ranise, A.; Arduino, N.; Bertolotto, M.B.; Montecucco, F.; Ottonello, L.; Dallegri, F.; To-gnolini, M.; Ballabeni, V.; Bertoni, S.; Barocelli, E. Synthesis and biological evaluation of A-pyrazolyl-A'-alkyl/benzyl/phenylureas: a new class of potent inhibitors of interleukin 8-induced neutrophil chemotaxis. J. Med. Chem., 2007, 50(15), 3618-3626.
65. Moriconi, A.; Cesta, M.C.; Cervellera, M.N.; Aramini, A.; Coniglio, S.; Cola-gioia, S.; Beccari, A.R.; Bizzarri, C.; Cavicchia, M.R.; Locati, M.; Galliera, E.; Di Benedetto, P.; Vigilante, P.; Bertini, R.; Allegretti, M. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2. J. Med. Chem., 2007, 50(15), 3984-4002.
66. Walter, I.; Austin, C.; Austin, R.; Bonnert, R.; Cage, P.; Christie, M.; Ebden, M.; Gardiner, S.; Grahames, C.; Hill, S.; Hunt, F.; Jewell, R.; Lewis, S.; Martin, I.; Nicholls, D.; Robinson, D. Evaluation of a series of bicyclic CXCR2 antagonists. Bioorg. Med. Chem. Lett., 2008, 18, 798-803.
67. Winters, M.P.; Crysler, C.; Subasinghe, N.; Ryan, D.; Leong, L.; Zhao, S.; Donatelli, R.; Yurkow, E.; Mazzulla, M.; Boczon, L.; Manthey, C.L.; Molloy, C.; Raymond, H.; Murray, L.; McAlonan, L.; Tomczuk, B. Carboxylic acid bioisosteres acylsulfonamides, acylsulfamides, and sulfonylureas as novel antagonists of the CXCR2 receptor. Bioorg. Med. Chem. Lett., 2008, 18, 1926-1930.
68. Cesarini, S.; Spallarossa, A.; Ranise, A.; Bruno, O.; Arduino, N.; Bertolotto, M.; Dallegri, F.; Tognolini, M.; Gobbetti, T.; Barocelli, E. 6-Amino-4-oxo-1,3-diphenyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carbonyl derivatives as a new class of potent inhibitors of Interleukin-8-induced neutrophil chemotaxis. Bioorg. Med. Chem., 2009, 17, 3580-3587.
69. Sablo-ne, M.R.; Cesta, M.C.; Moriconi, A.; Aramini, A.; Bizzarri, C.; Di Giacinto, C.; Di Bitondo, R.; Gloaguen, I.; Aschi, M.; Crucianelli, M.; Bertini, R.; Allegretti, M. Structure-activity relationship of novel phenylacetic CXCR1 inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 4026-4030.
70. O'Connor, B.J.; Leaker, B.; Barnes, P.; Nicholson, G.; Grahames, C.; Larsson, B.; Gaw, A.; Snell, N.; Newbold, P. Inhibition of LPS-induced neutrophilic inflammation in healthy volunteers. Eur. Respir. J., 2007, 30(Suppl. 1), 209s.
71. Lazaar, A.L.; Sweeney, L.E.; MacDonald, A.J.; Cooray, H.; Alexis, N.E.; Fuhr, R.; Tal-Singer, R. SB-656933, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in humans. Am. J. Respir. Crit. Care Med., 2009, 179, A6181.
72. Nicholls, D.J.; Tomkinson, N.P.; Wiley, K.E.; Brammel, A.; Bowers, L.; Grahames, C.; Gaw, A.; Meghani, P.; Shelton, P.; Wright, T. J.; Mallinder, P.R. Identification of a putative intracellular allos-teric antagonist binding-site in the CXC chemokines receptors 1= and 2. Mol. Pharmacol., 2008, 74(5), 1193-1202.
73. Kruijf, P.; Heteren, J.; Lim, H.D.; Conti, P.G.M.; Van der Lee, M.M.C.; Bosch, L.; Ho, K.-K.; Auld, D.; Ohlmeyer, M.; Smit, M.J.; Wijkmans, J.C.H.M.; Zaman, G.J.R.; Smit, M.J.; Leurs, R. Nonpetidergic allosteric antagonists differently bind to the CXCR2 receptor. J. Pharmacol. Exp. Ther., 2009, 329(2), 783-790.
74. Allegretti, M.; Bertini, R.; Bizzarri, C.; Beccari, A.; Mantovani, A.; Locati, M. Allosteric inhibitors of chemoattractant receptors: opportunities and pitfalls. Trends Pharm. Sci., 2008, 29(6), 280-286.